Question: In conclusion, in a large surveillance cohort, we found significantly increased, incremental cost associated with MAAGE-related services relative to usual-care medical services. We noted this increased cost for both adults and for children ≥5 years of age, and those higher costs persisted during the 30-day follow-up period from initial encounters. These findings suggest opportunities to prevent or intervene in the short-term period following a new MAAGE episode to mitigate costs, especially in adults ≥65 years of age. What does this mean in simplified terms?